Schweitzer Fachinformationen
Wenn es um professionelles Wissen geht, ist Schweitzer Fachinformationen wegweisend. Kunden aus Recht und Beratung sowie Unternehmen, öffentliche Verwaltungen und Bibliotheken erhalten komplette Lösungen zum Beschaffen, Verwalten und Nutzen von digitalen und gedruckten Medien.
The "Cancer Immunotherapy and Nanobiotechnology: An Interdisciplinary Approach" is the twenty fifth volume of the "Interdisciplinary Cancer Research" series, publishes comprehensive volume on cancer immunotherapy and nanobiotechnology. The volume starts with chapters on targeting mitochondria in cancer immunotherapy, immunotherapy in oncology, and cancer treatments through immunological pathways. Immune checkpoint inhibitors as well as engineered iPSC-based strategies are explained in other chapters after discussion on cancer stem cells. CAR NK, CAR T cells, and DC therapy are the subjects of the following chapters. Then tumor microenviroment in response to immunotherapy and T-cell responses during cancer immunotherapy through the use of imaging are explained. The second half of the volume is focused on application of nanobiotechnology in cancer, starting with general chapters on nanotechnology for cancer research, nanotechnology and cancer therapy strategies, nanomedicine based cancer immunotherapy, applications of nanocarrier systems in cancer treatment, and nanoformulations in cancer theranostics. Then the role of metal nanomaterials in cancer therapy, synthetic drug nanodelivery systems, nanoparticles loaded with cytotoxic agents, nanocarrier-mediated drug delivery, vesicular nanosystem, and nanoscale metal-organic frameworks for cancer-targeted therapy are explained. This is the main concept of Cancer Immunology Project (CIP), which is a part of Universal Scientific Education and Research Network (USERN). This interdisciplinary book will be of special value for those who wish to have an update on cancer immunotherapy and nanobiotechnology.
Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research and Technologies, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the Founder of Universal Scientific Education and Research Network (USERN). Prof. Rezaei has already been the Director of more than two hundred research projects and has designed and participated in several international collaborative projects. Prof. Rezaei is the editor, editorial assistant, or editorial board member of more than fifty international journals. He has edited more than one hundred international books, has presented more than a thousand lectures/posters in congresses/meetings, and has published more than 1,700 scientific papers in the international journals.
Targeting Mitochondria in Cancer Immunotherapy; Promises and Pitfalls.- Immunotherapy in Oncology: A Comprehensive Overview from a Pathological Perspective.- Cancer Treatments through Immunological Pathways: A Great Hope for Every Cancer Type and Every Patient?.- Cancer Immunotherapies Targeting Cancer Stem Cells: Concepts, Applications, and Advances.- Immune Checkpoint Inhibitors: Novel Therapies and Targets.- Advancing Cancer Immune Cell Therapies via Engineered iPSC-based Strategies.- CAR NK/CAR T cells: Emerging Immunotherapy of Cancer.- Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Therapy and Coagulopathies.- The Power of Imaging Techniques in CAR T-Cell Therapy Enhancement: Revolutionizing Cancer Treatment.- Discovery of T cell Epitopes for Cancer Immunotherapy.- Dendritic Cells in Cancer Immunotherapy: Current State and Future Prospects.- Tumor Microenvironment Role in Cancer Immunotherapy Response.- T-cell Responses During Cancer Immunotherapy Through the Use of CT, MRI, and PET.- Nanotechnology for Cancer Research (Diagnosis & Therapy): Recent Progress and Future Prospects.- Nanotechnology and Cancer Therapy Strategies.- Nanomedicine based Cancer Immunotherapy.- Applications of Nanocarrier Systems in Cancer Treatment.- Nanoformulations in Cancer Theranostics.- The Role of Noble Metal Nanomaterials in Cancer Therapy.- Synthetic and Natural Drug Nanodelivery Systems Used in Oncology Treatment.- Nanoparticles Loaded with Cytotoxic Agents: A Therapeutic Alternative against Cancer.- Advancements in Nanocarrier-Mediated Drug Delivery: Precision Strategies for Targeted Therapeutics and Improved Treatment Outcomes.- Vesicular Nanosystem as a Promising Platform for the Management of Cancer.- Nanoscale Metal-Organic Frameworks for Cancer-Targeted Therapy and Molecular Imaging.- Theranostic Properties of Iron Oxide Nanoparticles and Their Reprograming Properties on Tumor-associated Macrophages.- Composition of Proapoptotic Montmorillonite-Cytochrome C Nanoplates with High Anticancer Cytotoxicity: Monolayer Adsorption Approach.- Nanomaterials as Modulators of Non-apoptotic Regulated Cell Death Modes: Novel Options in Cancer Treatment.
Dateiformat: PDFKopierschutz: Wasserzeichen-DRM (Digital Rights Management)
Systemvoraussetzungen:
Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Wasserzeichen-DRM wird hier ein „weicher” Kopierschutz verwendet. Daher ist technisch zwar alles möglich – sogar eine unzulässige Weitergabe. Aber an sichtbaren und unsichtbaren Stellen wird der Käufer des E-Books als Wasserzeichen hinterlegt, sodass im Falle eines Missbrauchs die Spur zurückverfolgt werden kann.
Weitere Informationen finden Sie in unserer E-Book Hilfe.
